Home / Markets / Ireland

Market requirements · IE

Ireland

2 dated sources Reviewed 2026-08-20 Next review 2026-11-18

The HPRA detained 763,027 dosage units of falsified or unauthorised medicines in 2025. Ireland is English-speaking, so no local-language material is required.

Tell us the compounds you need for Ireland.Ask about Ireland

The regime

How compounds are classified in Ireland

Governing law and regulatorIreland's medicines regulator is the HPRA (Health Products Regulatory Authority). A vendor source cites the Irish Medicinal Products (Control of Manufacture) Regulations as the basis for offences involving unauthorised medicinal products, though this specific statutory link was not independently checked against the primary legislative text.
Direct regulator data, 2025 seizuresHPRA's own press release, corroborated by RTE, states HPRA detained 763,027 dosage units of falsified or illegal medicines in 2025; units presented as GLP-1 products for personal use rose from 1,582 in 2024 to 48,752 in 2025, roughly a 30x year-on-year increase, with personal-import consignments up 180% since 2024.
Prescription-only positionA vendor source, not independently verified against statutory text, states that selling any peptide as a medicinal product without HPRA/EMA marketing authorisation is an offence, and that BPC-157, TB-500, semaglutide, tirzepatide, ipamorelin, CJC-1295, GHK-Cu and retatrutide do not appear on Ireland's controlled drug schedules.
Enforcement postureThe seizure statistics demonstrate active, escalating HPRA enforcement including GLP-1 products; however, two further vendor claims, that HPRA has been 'unusually active' in research chemicals specifically, and that Ireland's 'Pangea XVII' action was the first EU customs interception of research-peptide vials, could not be confirmed against any HPRA or government source and should be treated as unconfirmed marketing copy.
Already supplying Ireland? Send the compounds and volumes you buy today and we will quote against them.Send your list

Your obligations

What a buyer in Ireland needs settled

  • Expect intensified HPRA scrutiny of GLP-1-class imports given the confirmed 30x year-on-year seizure increase.
  • Do not repeat vendor superlative claims, such as 'first ever' interception or 'unusually active' HPRA, as fact; this page could not verify them against a primary source.
  • Verify the controlled drug schedule status and the Irish Medicinal Products Regulations directly against statutory text rather than relying on the vendor summary.
  • Skip local-language (Irish/Gaeilge) investment for this market and put the budget into English-language compliance and SEO content instead.

We will ask about this at enquiry. We check the authorisations your activity requires before quoting, and we confirm the position per compound rather than for the market as a whole.

Sources

Check this yourself

Every position above traces to a dated public document. The authority, the document, the date and the link are below.

Authority and documentDateLink
HPRA
Over 750,000 units of illegal medicines detained by the HPRA in 2025
2025www.hpra.ie/news-events/news/article/over-750-000-units-of...
RTE
Illegal medicines seized
24 March 2026www.rte.ie/news/ireland/2026/0324/1564936-illegal-medicine...

Links go to the issuing body wherever one exists. Positions change. If you are relying on any of this, check the source rather than this page.

Market brief

Take the Ireland brief as a PDF

The regime, the buyer obligations and all 2 sources, dated and linked, in one document you can forward.

Nearby

Elsewhere in the EU and nearby markets

Buyers supplying one of these usually supply the others. The requirements are not the same.

CodeMarketSources
RORomania3 sourcesANMDMR operates under the EU medicines framework and has publicly identified a...
BGBulgaria5 sourcesThe BDA regulates under the national medicines law and participates in the EU ...
LTLithuania4 sourcesThe VVKT regulates under the Farmacijos istatymas and requires a wholesale dis...
LVLatvia4 sourcesThe ZVA regulates under the Farmacijas likums and has published dated GLP-1 sa...

Scope

How to use this page

A summary of the published regulatory position in Ireland as at 2026-08-20, written for procurement teams deciding how to source. Every source is dated and linked so it can be checked at origin.

It is not legal advice. Full terms of supply, including where responsibility sits, are set out in our terms of supply.

Questions

Supplying into Ireland

Do you supply into Ireland?

We supply businesses that hold the authorisations their activity requires. Whether a specific compound can be supplied into Ireland depends on that compound and on your authorisations, and we confirm it per compound at the enquiry stage.

Who carries the compliance obligation?

The importer of record and the party placing the product on the market, which is the buyer. We supply the batch documentation that supports your file. We cannot hold your authorisations for you.

How current is this page?

It was reviewed on 2026-08-20 and is scheduled for review again on 2026-11-18. Every source is dated and linked, so you can check the original.

We already supply into Ireland. What changes if we source from you?

The batch documentation. You receive a Certificate of Analysis per batch, which can be issued under your own brand. The import and market-placing responsibilities stay where they are.

Is this legal advice?

No. It is a summary of the regulatory positions those authorities have published, as at the review date above. Take advice in your own market before you rely on it.

Enquire about supply into Ireland

Tell us the compounds and your authorisations. We confirm per compound before anything ships.

Anything else you already know. All optional.

We supply businesses across the EU, and we reply within one working day.